Therapeutic drug monitoring of anti-tumor necrosis factor agents: lessons learned and remaining issues.
Journal
Current opinion in pharmacology
ISSN: 1471-4973
Titre abrégé: Curr Opin Pharmacol
Pays: England
ID NLM: 100966133
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
27
05
2020
revised:
29
08
2020
accepted:
17
09
2020
pubmed:
1
11
2020
medline:
14
10
2021
entrez:
31
10
2020
Statut:
ppublish
Résumé
Therapeutic drug monitoring (TDM) of anti-tumor necrosis factor agents (anti-TNFs) has received extensive attention due to its potential for improving treatment outcomes in patients with inflammatory bowel diseases. However, the benefits of applying TDM in clinical practice remain largely unclear due to a lack of evidence from the available prospective randomized controlled studies. The questionable evidence for TDM obtained in these studies can be caused by several design suboptimalities, including long turnaround times of sample analysis, use of inappropriate exposure targets, insufficiently precise algorithms for dose optimization, and inapt trial designs. In future studies, model-informed precision dosing in combination with rapid testing methods is recommended to maximize the potential of TDM of anti-TNFs.
Identifiants
pubmed: 33128934
pii: S1471-4892(20)30088-6
doi: 10.1016/j.coph.2020.09.007
pii:
doi:
Substances chimiques
Biological Factors
0
Gastrointestinal Agents
0
Tumor Necrosis Factor-alpha
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
53-59Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.